“Cannabis is a common recreational drug that is generally considered to have low addictive potential.
However an increasing number of cannabis users are seeking treatment for dependence on the drug.
There is interest in using agonist (substitution) pharmacotherapies to treat cannabis dependence and here we outline a novel approach involving a buccal spray (Nabiximols) that contains tetrahydrocannabinol (THC) and cannabidiol (CBD).
We review recent research with Nabiximols and highlight findings relevant to clinical practice.”